Regulatory Request NIS in Korea

Boehringer Ingelheim658 enrolled

Overview

To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting

Study Type

OBSERVATIONAL

Enrollment

658

Conditions

Diabetes Mellitus, Type 2

Interventions

JARDIANCE DUO®DRUG

empagliflozin and metformin

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have started at first time on JARDIANCE DUO® in accordance with the approved label in Korea * Age ≥19 years at enrolment * Patients who have signed on the data release consent form Exclusion Criteria: * Patients with previous exposure to JARDIANCE®, JARDIANCE DUO® * Hypersensitivity to active ingredients empagliflozin and/or metformin or to any of the excipients * Moderate (stage 3b) and severe renal failure (CrCl \< 45 ml/min or eGFR \< 45 ml/min/1.73 square meter) * Acute conditions with the potential to alter renal function such as: dehydration, severe infection, cardiovascular collapse (shock), acute myocardial infarction, sepsis * Type1 diabetes, acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, history of a ketoacidosis (type 1 diabetes and diabetic ketoacidosis should be treated with insulin). * Congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure * Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials) * Intravascular administration of iodinated contrast media may lead to acute renal failure and has been associated with lactic acidosis in patients receiving metformin. Therefore, in patients with eGFR \> 60ml/min/1.73m2, JARDIANCE DUO® must be discontinued prior to, or at the time of the test and not be reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and has not deteriorated further. In patients with moderate renal impairment (eGFR 45-60 ml/min/1.73m2), JARDIANCE DUO® must be discontinued 48 hours before administration of iodinated contrast media and not be reinstituted until at least 48 hours afterwards, and only after renal function has been re-evaluated and has not deteriorated further. * In patients with severe infections or severe traumatic systemic disorders, JARDIANCE DUO® should be temporarily suspended, and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal. * JARDIANCE DUO® should be temporarily suspended for any surgical procedure(except minor procedures not associated with restricted intake of food and fluids)before 48 hours, and not be reinstituted until 48 hours afterwards, after renal function has been evaluated as normal. * Patients with malnutrition, starvation, hypostheniam pituitary or adrenal insufficiency * Impaired hepatic function (since impaired hepatic function has been associated with some cases of lactic acidosis, JARDIANCE DUO® should generally be avoided in patients with clinical or laboratory evidence of hepatic disease), pulmonary infarction, severe respiratory impairment, any condition associated with hypoxemia, excessive alcohol intake, GI disorders such as dehydration, diarrhoea or vomiting * Pregnant women, women who may be pregnant, nursing women * Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock * Current participation in other clinical trials

Locations (20)

Korea University Ansan Hospital

Ansan, South Korea

Hyewon Medical Foundation Sejong Hospital

Bucheon-si, South Korea

Outcomes

Primary Outcomes

Percentage of Participants With Any Adverse Events

Percentage of participants with any adverse events was reported. The 95% Confidence Interval for the percentage of participants with adverse event was calculated by Exact Method.

Time frame: From baseline (Visit 1) until last visit (the last follow-up visit a patient actually received during the study), up to 349 days.

Percentage of Participants With Adverse Events Relating to Study Drug

Percentage of participants with adverse events relating to study drug was reported. The 95% Confidence Interval for the percentage of participants with adverse event was calculated by Exact Method.

Time frame: From baseline (Visit 1) until last visit (the last follow-up visit a patient actually received during the study), up to 349 days.

Percentage of Participants With Unexpected Adverse Events

Percentage of participants with unexpected adverse events was reported. The 95% Confidence Interval for the percentage of participants with adverse event was calculated by Exact Method.

Time frame: From baseline (Visit 1) until last visit (the last follow-up visit a patient actually received during the study), up to 349 days.

Percentage of Participants With Adverse Events of Special Interest

Percentage of participants with adverse events of special interest was reported. The 95% Confidence Interval for the percentage of participants with adverse event was calculated by Exact Method.

Time frame: From baseline (Visit 1) until last visit (the last follow-up visit a patient actually received during the study), up to 349 days.

Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug

Percentage of participants with adverse events leading to discontinuation of the drug was reported. The 95% Confidence Interval for the percentage of participants with adverse event was calculated by Exact Method.

Time frame: From baseline (Visit 1) until last visit (the last follow-up visit a patient actually received during the study), up to 349 days.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.